

1 **Title:** Autoimmune profiling suggests paraneoplastic etiology in pediatric ROHHAD
2
3 Caleigh Mandel-Brehm*, PhD, Department of Biochemistry and Biophysics, University
4 of California, San Francisco, CA
5 Leslie A. Benson*, MD, Department of Neurology, Harvard Medical School, Boston, MA
6 Baouyen Tran*, PhD, Weill Institute for Neurosciences, Department of Neurology,
7 University of California, San Francisco, CA
8 Andrew F. Kung, BA, Department of Biochemistry and Biophysics, University of
9 California, San Francisco, CA
10 Sabrina A. Mann, Department of Biochemistry and Biophysics, University of California,
11 San Francisco, CA
12 Sara E. Vazquez, BS, Department of Biochemistry and Biophysics, University of
13 California, San Francisco, CA
14 Hanna Retallack, PhD, Department of Biochemistry and Biophysics, University of
15 California, San Francisco, CA
16 Hannah A. Sample, BS, Department of Biochemistry and Biophysics, University of
17 California, San Francisco, CA
18 Kelsey C. Zorn, MHS, Department of Biochemistry and Biophysics, University of
19 California, San Francisco, CA
20 Lillian M. Khan, BS, Department of Biochemistry and Biophysics, University of
21 California, San Francisco, CA
22 Lauren M. Kerr, BA, Department of Neurology, Boston Children's Hospital, Boston, MA

- 23 Patrick L. McAlpine, BS, Otolaryngology Head and Neck Surgery Research Division,
24 Stanford University, Stanford, CA
- 25 Lichao Zhang, PhD, Chan Zuckerberg Biohub, Stanford, CA
- 26 Frank McCarthy, BS, Chan Zuckerberg Biohub, Stanford, CA
- 27 Joshua E. Elias, PhD, Chan Zuckerberg Biohub, Stanford, CA
- 28 Umakanth Katwa, MD, Department of Pulmonary Medicine, Sleep Center, Boston
29 Children's Hospital, Boston, MA
- 30 Christina M. Astley, MD, ScD Division of Endocrinology & Computational Epidemiology,
31 Boston Children's Hospital, Boston, MA
- 32 Stuart Tomko, MD, Department of Neurology, Washington University, St. Louis, MO
- 33 Josep Dalmau, MD, PhD, Catalan Institution for Research and Advanced Studies
34 (ICREA), Hospital Clinic-Idibaps, University of Barcelona, Barcelona, Spain
- 35 William W. Seeley, MD, Memory and Aging Center, Department of Neurology,
36 University of California, San Francisco, CA
- 37 Samuel J. Pleasure, MD, PhD, Weill Institute for Neurosciences, Department of
38 Neurology, University of California, San Francisco, CA
- 39 Michael R. Wilson, MD, MAS, Weill Institute for Neurosciences, Department of
40 Neurology, University of California, San Francisco, CA
- 41 Mark P. Gorman**, MD, Department of Neurology, Harvard Medical School, Boston, MA
- 42 Joseph L. DeRisi**, PhD, Chan Zuckerberg Biohub, Department of Biochemistry and
43 Biophysics, University of California, San Francisco, CA
- 44
- 45 *Authors contributed equally to this work

46 **Co-Corresponding authors

47 **Corresponding Author Information**

48 Name: Mark P. Gorman

49 Address: 300 Longwood Ave, Boston, MA, 02115

50 Email: mark.gorman@childrens.harvard.edu

51 Phone: 857-218-4794

52

53 Name: Joseph L. DeRisi

54 Address: 1700 4th street, QB3 room 404, San Francisco, CA 94110

55 Email: joe@derisilab.ucsf.edu

56 Phone: 415-418-4794

57

58

59

60

61

62

63

64

65

66

67

68

69 **Abstract**

70 ROHHAD (Rapid-onset Obesity with Hypothalamic Dysfunction, Hypoventilation and
71 Autonomic Dysregulation) is a rare, yet severe pediatric disorder resulting in
72 hypothalamic dysfunction and frequent sudden death. Genetic and other investigations
73 have failed to identify an etiology or diagnostic test. Frequent co-occurrence of
74 neuroblastic tumors (NTs) and cerebrospinal fluid inflammation point to an autoimmune
75 paraneoplastic neurological syndrome (PNS); however, specific anti-neural
76 autoantibodies, a hallmark of PNS, have not been identified. Here, we screened
77 antibodies from a curated cohort of ROHHAD patients (n=9) and controls (n=150) using
78 a programmable phage display of the human peptidome (PhIP-Seq). Our ROHHAD
79 cohort exhibited frequent association with NTs (8/9) and features consistent with
80 autoimmune etiology. Autoantibodies to Zinc finger and SCAN domain-containing
81 protein 1 (ZSCAN1) were discovered and orthogonally validated in 7 of 9 ROHHAD
82 patients, all of whom had NTs, and shown to be absent in non-ROHHAD pediatric
83 patients with NTs. Notably, human ZSCAN1 expression was confirmed in ROHHAD
84 tumor and healthy human hypothalamus. Our results support the notion that tumor-
85 associated ROHHAD is a pediatric PNS, potentially initiated by an immune response to
86 peripheral NT. ZSCAN1 autoantibodies may aid in an accurate diagnosis of ROHHAD,
87 thus providing a means toward early detection and treatment. Lastly, given the absence
88 of the *ZSCAN1* gene in rodents, our study highlights the value of human-based
89 approaches in addition to the classical rodent-based approaches for detecting novel
90 PNS subtypes.

91

92 **Main**

93 Rapid-onset Obesity with Hypothalamic Dysfunction, Hypoventilation and Autonomic
94 Dysregulation (ROHHAD) is a poorly understood pediatric syndrome with high morbidity
95 and mortality, distinguished by its unique progression of multi-system derangements^{1,2}.
96 Variable degrees of hypothalamic and presumed brainstem dysfunction manifest after
97 age two as obesity, autonomic dysregulation and alveolar hypoventilation with risk of
98 sudden death from respiratory or autonomic dysfunction¹⁻⁶. Neuropsychiatric changes
99 and seizures have been described⁷⁻⁸. Detailed longitudinal follow up describing
100 ROHHAD's natural history is limited⁹. Although incurable, early supportive care
101 including respiratory support for hypoventilation may reduce morbidity^{10,11}. Diagnosis
102 remains difficult given lack of biomarkers and overlap with other pediatric disorders
103 including congenital central hypoventilation syndrome (CCHS), Prader-Willi syndrome
104 and other forms of genetic and non-genetic obesity¹²⁻¹⁵. Although recognized as a
105 distinct disorder since 2000, ROHHAD is rare with fewer than 200 reported cases^{1,5}.
106 The etiology is unclear.

107 Thus far, most etiologic investigations into ROHHAD have focused on genetic
108 susceptibility, without consistent results¹⁶⁻¹⁹. The presence of neuroblastic tumor (NT)
109 defines a large subset of patients with ROHHAD (30-100% depending on the series),
110 sometimes referred to as ROHHAD-NET^{5,20}. NTs are similarly associated with CCHS, a
111 genetic condition, and opsoclonus-myooclonus syndrome (OMS), an autoimmune
112 paraneoplastic neurological syndrome (PNS)²¹⁻²³. With respect to ROHHAD, several
113 observations suggest an immune-mediated disease, including the presence of
114 oligoclonal bands in cerebrospinal fluid (CSF) and immune-cell infiltrates in brain,

115 including hypothalamus and brainstem at autopsy²⁴⁻²⁹. In addition, some patients with
116 ROHHAD have variable improvement with immunotherapy^{7,30,31}. Establishing ROHHAD
117 as a PNS would have important implications for developing diagnostic biomarkers,
118 highlighting the need for tumor identification and resection, and advancing the use of
119 immunosuppressive treatments³².

120

121 On a molecular level, a PNS can be defined by its association with autoantibodies to
122 specific onconeural antigens, or proteins expressed in both the pathogenic tumor and
123 healthy nervous system³³. Despite a suspicion of PNS in ROHHAD^{29,34}, evidence of
124 anti-neural reactivity is limited and an associated onconeural antigen has not been
125 identified. Here, we deployed human-specific phage-display immunoprecipitation and
126 next-generation sequencing (PhIP-Seq) and complementary techniques to investigate a
127 possible paraneoplastic etiology in ROHHAD. We find that autoantibodies to protein
128 Zinc finger and SCAN domain-containing protein 1 (ZSCAN1) are robustly associated
129 with ROHHAD and may be useful as a diagnostic biomarker and advancing knowledge
130 of this poorly understood disease.

131

132 **Results**

133 **Clinical profile of ROHHAD cohort**

134 The ROHHAD cohort consisted of 9 patients (ROHHAD-1 through 9) selected on the
135 basis of clinical suspicion for ROHHAD syndrome, without alternative diagnosis
136 (Table1). Each patient was found to exhibit defining features of ROHHAD syndrome
137 including rapid-onset of obesity between 2-5 years of age and multiple additional

138 features of hypothalamic dysfunction (Table1). Three patients were described
139 previously^{1,7,35}. Hypoventilation was present in 8/9 at diagnosis. Eight of 9 patients were
140 found to have NT (ROHHAD-1 through 8), while a single patient in this cohort was not
141 known to have a tumor (ROHHAD-9), although work-up was limited to chest x-ray and
142 chest MRI without abdominal imaging. Eight of 9 subjects had clinical genetic testing
143 without genetic syndromes identified to explain their phenotypes. Features suggestive
144 of a neuroinflammatory process include comorbid autoimmune diseases (2/9), elevated
145 CSF neopterin (3/9), marked inflammation noted within resected tumor tissue (4/8) and
146 matched or CSF-specific oligoclonal bands (5/8 tested). Improvement in symptoms was
147 observed in 6/7 patients treated acutely with supportive care, tumor resection and
148 immune therapy at diagnosis. Response to immunotherapy was most clearly
149 demonstrated in ROHHAD-6 in whom CO₂ retention improved and worsened in parallel
150 with changing steroid doses (Supplemental Figure 1). Similarly, neurobehavioral
151 symptoms improved for ROHHAD-7⁶. Additional clinical details pertaining to
152 autoimmune features and neurologic phenotypes for the ROHHAD cohort are provided
153 in Supplemental Table 1 and Supplemental Table 2, respectively.

154

155 **Clinical profile of control cohorts**

156 Control cohort 1 (CC1) and control cohort 2 (CC2) were assembled for PhIP-seq
157 screening and validation experiments, respectively. CC1 represents plasma from 100
158 de-identified blood donors courtesy of New York Blood Center. CC2 represents 27 de-
159 identified healthy volunteers (plasma n =3; sera n = 17, CSF n =7) and 26 clinically
160 relevant pediatric controls, Pediatric controls include: childhood obesity + NT (n =1), and

161 children with OMS (with NT n = 10, without NT n=15). Clinical details and demographics
162 pertaining to controls is provided in Supplemental Table 3 (CC1) and Supplemental
163 Table 4 (Pediatric controls OMS and Obesity +NT).

164

165 **Screening for autoantibodies using rodent based approaches**

166 Immunohistochemical screening of patient antibodies against neural tissue, typically
167 rodent, is a classical approach for identifying cryptic autoimmune etiologies among
168 idiopathic neurological syndromes³⁶⁻⁴⁰. In two independent laboratories (JLD, SJP),
169 antibodies in CSF from ROHHAD-1 through 6 were tested for immunoreactivity against
170 mouse brain tissue (Supplemental Methods). Neither identified anti-neural reactivity in
171 any patient (Supplemental Figure 2). Additional, independent assessment of
172 autoantibodies to extracellular neural targets were also tested in 4 patients in this cohort
173 using pre-established protocols for fixed³⁹ and live rat neurons⁴⁰. All studies were
174 negative (JD, see supplemental Table 1).

175

176 **Screening for autoantibodies using human-specific Phage-Display**

177 **Immunoprecipitation and Sequencing (PhIP-Seq)**

178 The PhIP-seq library employed here displays a representation of the human proteome
179 and has been used previously for detecting diagnostic PNS autoantibodies⁴⁰⁻⁴¹. As part
180 of a discovery pilot, we screened CSF from 3 ROHHAD patients (ROHHAD 1-3) and
181 plasma from CC1 (n=100). Individual PhIP-seq datasets were normalized to 100,000
182 reads (RP100K) and protein RP100Ks were averaged according to cohort. To aid in
183 candidate identification, ROHHAD-specific Z-score enrichments were generated, using

184 CC1 values (see methods). All proteins with a ROHHAD mean RP100K > 0 were
185 plotted relative to Z-score enrichments (Figure 1). Candidate antigens were expected to
186 satisfy the following criteria in at least 2 patients: a minimum level of recovery
187 (RP100K>50) and minimum Z-score enrichment (>3). Of the ~20,000 protein
188 possibilities, only 1 protein, ZSCAN1, satisfied these criteria. Using the same criteria
189 above, enrichment of ZSCAN1 was not observed in other previously published
190 autoimmune cohorts screened on the same PhIP-Seq platform including PNS
191 syndromes anti-Yo (n= 36)⁴¹, anti-Hu (n= 44)⁴¹, anti-Ma2 (n =2)⁴², anti-KLHL11 (n =7)⁴²
192 or patients with systemic Autoimmune Polyglandular Syndrome Type I (n=39)⁴³.

193

194 **Orthogonal validation assays**

195 To further investigate the association of ZSCAN1 and ROHHAD syndrome, we repeated
196 PhIP-seq with an expanded ROHHAD cohort (including the 4 original patients) and new
197 set of controls (CC2). For all samples, ZSCAN1 RP100K is reported, as well as, Z-score
198 enrichment based on our background control dataset CC1 (ZSCAN1 mean = 8.18
199 RP100K, standard deviation = 32.53 RP100K), with Z-score > 3 considered positive.
200 We reproduced the association between ZSCAN1 and ROHHAD, showing enrichment
201 in 7 of 9 ROHHAD patients (ROHHAD-1 to 7) and 0 of 50 samples from CC2 (Figure 2,
202 *top*). We next leveraged peptide-level data and found antigenicity within ZSCAN1 was
203 largely restricted to the C-terminal of ZSCAN1, with patients displaying enrichment of
204 overlapping peptides, increasing confidence in our findings (Supplemental Figure 3).
205 Intriguingly, patients ROHHAD-1 through 7 shared a common 11 amino acid (AA)
206 epitope.

207

208 To confirm ZSCAN1 enrichment in our ROHHAD cohort was antibody-mediated, we
209 tested for IP of recombinant ZSCAN1 in two orthogonal assays, including a radioligand
210 binding assay (RLBA) and 293T cell-based overexpression assay (CBA). For the 6
211 patients with paired CSF and sera (ROHHAD 1-6), ZSCAN1 enrichment in one sample
212 type was sufficient to be called positive in a given assay. First, the RLBA with *in vitro*
213 transcribed and translated full length ZSCAN1 protein revealed positive IP (fold change
214 > 10) by ROHHAD patients 1 through 7 (sera n = 7/7; paired CSF n = 6/6) and no
215 enrichment in CC2 healthy controls (Figure 2B). Low-level enrichment of ZSCAN1 was
216 observed in 2 patients negative by PhIP-seq; ROHHAD-9 and OMS-4. Second, using
217 immunocytochemistry and 293T cells expressing full-length ZSCAN1, we show
218 colocalization of human antibodies with commercial antibody to ZSCAN1 for ROHHAD
219 patients 1 through 7 (sera n=2 ROHHAD-1 and 3; CSF n = 6 ROHHAD-1 through 6).
220 Co-localization is not observed for ROHHAD-8, ROHHAD-9 or controls, including OMS-
221 4 (Figure 2C). Taken together, ROHHAD-1 through 7 reproduced ZSCAN1 enrichment
222 in two antibody-based orthogonal assays, thus limiting possibility of false-positives and
223 validating autoantibodies to ZSCAN1 in this cohort⁴⁴.

224

225 Of note for 293T CBAs, we observed increased sensitivity to ZSCAN1 autoantibody
226 detection using CSF compared to sera. This is exemplified best in data collected from
227 the 6 patients with paired CSF and sera (ROHHAD-1 through 6). In 293T CBAs,
228 ZSCAN1 autoantibodies were detected using 6/6 CSF samples (Supplemental Figure
229 4). In contrast, only 2/6 paired sera were positive (Supplemental Figure 5). To rule out

230 technical artifacts, sera samples were re-tested on CBA at several dilutions 1:100,
231 1:1000, 1:2000 and 1:5000, with no change in seronegativity. We further tested for
232 recognition of ZSCAN1 autoantibodies using whole cell lysates prepared from 293T
233 cells overexpressing ZSCAN1. When western blotting denatured lysates with CSF and
234 sera we again observed positive signal with 6/6 CSF but only 2/6 paired sera
235 (Supplemental Figure 6).

236

237 **Testing antigen expression in tumor and brain**

238 Typically, autoantibodies associated with PNS target antigens that are expressed in
239 relevant tumor and healthy brain, otherwise known as onconeural antigens³⁸. To test for
240 tumor expression of ZSCAN1, one NT from ROHHAD-3 was sectioned and
241 immunostained with a previously validated commercial antibody to ZSCAN1
242 (Supplemental Figure 4 through 6). A rabbit secondary only control was used to test for
243 nonspecific staining of Rabbit IgG to infiltrating human IgG and Fc proteins in the tumor.
244 ZSCAN1 expression was apparent in the ROHHAD-associated tumor (Figure 3). To test
245 for hypothalamic expression of ZSCAN1, mass spectrometry analysis was performed
246 using immunoprecipitation from human hypothalamic lysates using commercial
247 antibodies to ZSCAN1. ZSCAN1 peptides were readily detectable, consistent with
248 protein expression in this tissue (Supplemental Table 5).

249

250 **Discussion**

251 In this work, we describe a proteome-wide screen for autoantibodies in patients with
252 ROHHAD, a complex, diagnostically challenging syndrome with severe and often life-

253 threatening symptoms^{1,2}. By comparing antibody profiles from ROHHAD patients to a
254 large set of clinically relevant controls, we found autoantibodies to ZSCAN1 are a
255 putative biomarker of ROHHAD, and thus have potential utility in identifying ROHHAD
256 earlier in the disease course.

257
258 All patients in this ROHHAD cohort (n= 9/9) exhibited the defining symptoms of the
259 syndrome including rapid-onset obesity and hypothalamic dysfunction, with an onset
260 between two to five years of age^{1,2}. NTs were present in 8/9 patients. Autoantibodies to
261 ZSCAN1 were identified in 7 of 9 patients tested (sera n=7/9, paired CSF n=5/6) by
262 PhIP-Seq, all of whom had NTs. Each of the 7 PhIP-Seq positive samples (ROHHAD-1
263 through 7) were validated by at least two orthogonal assays, including 293T CBA and
264 RLBA. Two assay validation limits the possibility of false-positive results and is
265 increasingly accepted as a prerequisite for defining bona fide autoantigens^{36,44}.

266
267 Two ROHHAD patients (ROHHAD-8 and 9) were negative for ZSCAN1 autoantibodies,
268 although CSF was not available for testing. Interestingly, ROHHAD-8 was in clinical
269 remission when their sera was collected and at an older age compared to other patients
270 (age range = 2 – 10 years, median 3 years), who all exhibited active symptoms at
271 sample collection. ROHHAD-9 did not have a tumor identified but exhibited the
272 ROHHAD phenotype and active disease. Future experiments to determine the
273 association of ZSCAN1 antibodies and ROHHAD syndrome in the absence of NT are
274 warranted.

275

276 Previous clinical reports suggested ROHHAD could be a PNS by virtue of its co-
277 occurrence with a tumor type already associated with a different PNS (OMS), clinical
278 features of autoimmunity and the failure to identify consistent genetic associations^{3,7,8,16-}
279 ^{19,24,26-31}. Our findings collectively support the notion of a PNS etiology. First,
280 autoantibodies to the molecular antigen (ZSCAN1) were found in the majority (7/9) of
281 ROHHAD cases, and in all from cases with a NT identified. Second, ZSCAN1
282 expression in human hypothalamus is consistent with the target tissues affected in
283 ROHHAD patients. Third, ZSCAN1 was found to be expressed in NT tissue from a
284 patient with ROHHAD. Lastly, the presumed intracellular localization of ZSCAN1
285 (www.uniprot.org, www.proteinatlas.org), together with our expression in ROHHAD NTs
286 as well as healthy nervous system tissue, is reminiscent of other classical PNS
287 onconeural antigens. Antibodies to intracellular onconeural antigens are a biomarker for
288 a major subtype of PNS, such as cerebellar degeneration-related protein 2-like in anti-
289 Yo PNS and neuronal ELAV-like proteins 2,3,4 in anti-Hu PNS³³. In these cases,
290 autoantibodies themselves are not thought to be directly pathogenic, and the diseases
291 are often less consistently responsive to tumor resection and immunotherapy compared
292 to PNS with antibodies to extracellular antigens. Consistent with the hypothesis of PNS,
293 ROHHAD patients have variable responses (duration and magnitude) to immunotherapy
294 or tumor resection and may respond better to earlier, more aggressive regimens^{3,7,30,31}.
295
296 The ZSCAN1 protein is a putative zinc finger transcription factor (znTF) that contains a
297 single SCAN domain and 3 Cysteine₂-Histidine₂ (C₂H₂) zinc finger domains
298 (uniprot.org). Despite nearly equal representation of SCAN domain (84 AA) and C₂H₂

299 domains (100 AA), antigenicity in ZSCAN1 is biased to the C₂H₂ domains, a functional
300 region for DNA and RNA binding⁴⁵. Further, although ~ 700 human proteins containing
301 C₂H₂ domains with the motif C-X₂₋₄-C-X₁₂-H-X₂₋₆-H (where X is any AA) are present in
302 our PhIP-seq library, no other ZnTF's were significantly enriched in more than one
303 patient (Z-score > 1), highlighting the specificity of the motif identified by PhIP-Seq.
304 Importantly, the *ZSCAN1* gene lacks a genetic ortholog in rodents, including mice and
305 rats, with evolutionary divergence towards primate-specificity in the C₂H₂ region⁴⁵⁻⁴⁸.
306 These observations suggest the putative epitope within ZSCAN1 has a high likelihood
307 of being exclusive to primate. To our knowledge, a primate-specific epitope in
308 autoimmune disease has not yet been described.

309
310 A common autoantibody among ROHHAD patients suggests a route to a molecular
311 diagnostic. Here we demonstrate the value of the human-specific PhIP-seq approach
312 for ROHHAD biomarker discovery. *ZSCAN1* has no genetic ortholog in rodents, so the
313 classical rodent based approach for PNS autoantibody detection failed. Our results
314 suggest CBAs or RLBA on CSF may be sufficient to detect ZSCAN1 autoantibodies in
315 a clinical lab setting. In the case of ROHHAD, these results also suggest that CSF may
316 be the most sensitive sample type for testing, since ZSCAN1 was not always detectable
317 in sera, particularly on CBA, as is true for many PNS.

318
319 To summarize, we provide a robust finding of autoantibodies to ZSCAN1 as a marker
320 for tumor-associated pediatric ROHHAD. ZSCAN1 expression in tumor and human
321 hypothalamus provides further evidence to support the clinical suspicion that ROHHAD

322 is a novel type of PNS. This is the first identified intracellular antigen in a PNS unique to
323 children. Further experiments are required to test the utility of ZSCAN1 autoantibodies
324 for diagnosis in ROHHAD patients with and without tumors, define the clinical spectrum
325 of PNS ROHHAD and to understand how immune targeting of ZSCAN1 contributes to
326 the dramatic clinical complications seen in patients with ROHHAD syndrome.

327

328 **Methods**

329 All relevant ethical regulations were followed regarding animal experiments and human
330 research participant involvement. We have obtain informed consent from all
331 participants and/or their parents.

332

333 **Patient recruitment**

334 All local IRB regulations were followed at Boston Children's Hospital (protocol #09-02-
335 0043) and University of California, San Francisco (protocol #13-12236). All patient
336 specific data was extracted by chart review (LB, LK, ST) and samples obtained
337 following family consent. ROHHAD subjects were identified by pediatric neuro-
338 immunologists (L.B. or S.T.) on the basis of clinical suspicion for ROHHAD syndrome,
339 without alternative diagnosis.

340

341 **Autoantibody discovery and validation**

342 For autoantibody discovery, we utilized the PhIP-Seq library and experimental protocol
343 as previously described.⁴² PhIP-seq datasets were analyzed with a formalized analysis
344 pipeline (generated in-house) that includes alignment of DNA reads to input library⁴⁹,

345 conversion to peptide reads, summing of peptides by protein ID, normalization to
346 100,000 reads (RP100K) and calculating mean RP100K for each protein. Alignment of
347 sequencing reads to the input library on a peptide-level was performed with
348 RAPsearch2⁴⁹ and command line ' /data/bin/rapsearch -d input_library -q
349 read1_location -o output_location -z 12 -v 1 -b 0'. A Z-score enrichment for each protein
350 was calculated based on mean RP100K generated from a large set of healthy controls.
351 Z-score formula = $(\text{protein}_x \text{ mean RP100K}_{\text{Experimental}} - \text{protein}_x \text{ mean RP100K}_{\text{control}}) /$
352 $(\text{Standard Deviation of protein}_x \text{ in controls})$.

353

354 **Onconeural antigen investigation**

355 To examine candidate autoantigen expression in ROHHAD tumor and healthy human
356 brain we used immunohistochemistry and immunoprecipitation-mass spectrometry (IP-
357 MS), respectively. For tumor examination, fresh frozen tumor was embedded,
358 sectioned, fixed on slides, stained and imaged according to standard procedures
359 (Supplemental Methods). To detect ZSCAN1 we immunostained with commercial
360 antibody to ZSCAN1 (Rabbit, Thermo Fisher Scientific, PA552488) and anti-rabbit
361 secondary. For IP-MS experiments, ~100 milligrams of frozen human hypothalamus
362 was homogenized and prepared for IP and subsequent MS analysis (Supplemental
363 Methods). For IP, lysate was diluted to 0.5 mg/mL and one of the following antibodies
364 was added at 1ug/mL: Rabbit anti-ZSCAN1 (Thermo Fisher Scientific, PA552488),
365 Rabbit anti-ZSCAN1 (Sigma Aldrich HPA007938), Rabbit IgG control (Thermo Fisher
366 Scientific, 31235). Positive identification of ZSCAN1 required detection with two

367 commercial antibodies and absence from isotype control. Two technical replicates were
368 performed.

369

370 **Animal Protocol**

371 All animal protocols were in accordance with the regulations of the National Institute of
372 Health and approved by the University of California San Francisco Institutional Animal
373 Care and Use Committee (IACUC). Wildtype C57B6 mice were obtained from Jackson
374 Laboratories (Bar Harbor, ME, USA). Adult mice (> postnatal day 42) were used for
375 immunohistological screening of human patient antibodies.

376

377 **Data availability**

378 Original data contributing to the main findings in our study is provided on Dryad
379 repository (temporary link for review: [https://datadryad.org/stash/share/-](https://datadryad.org/stash/share/-vpGClCcsEFX1bVTwmPAqh3K_6errf8vkOo6k3vPnUk)
380 [vpGClCcsEFX1bVTwmPAqh3K_6errf8vkOo6k3vPnUk](https://datadryad.org/stash/share/-vpGClCcsEFX1bVTwmPAqh3K_6errf8vkOo6k3vPnUk)). The dryad repository includes
381 PhIP-Seq analysis and RLBA analysis of ZSCAN1 (Figure 1, Figure 2 a,b), Mass
382 Spectrometry search results (Supplemental Table 5), original microscopy images
383 (Figure 2c, Supplemental Figure 2,4,5), original blots (Supplemental Figure 6). There
384 are no data restrictions for this study.

385

386 **Additional Methods**

387 Full experimental details regarding PhIP-Seq screening for candidate autoantibodies,
388 orthogonal validation assays, indirect immunofluorescence screening for anti-neural

389 antibodies on rodent tissue, immunohistochemistry of ROHHAD tumor tissue and IP-MS
390 of human brain are provided in Supplemental Methods.

391

392 **References**

- 393 1. Katz, E.S., Mcgrath, S., Marcus, C.L. Case Reports Late-Onset Central
394 Hypoventilation With Hypothalamic Dysfunction: A Distinct Clinical Syndrome.
395 *Pediatr Pulmonol.* 68, 62-8 (2000).
- 396 2. Ize-Ludlow, D., et al. Rapid-onset obesity with hypothalamic dysfunction,
397 hypoventilation, and autonomic dysregulation presenting in childhood. *Pediatrics*
398 120, e179-88 (2007).
- 399 3. Ibáñez-Micó, S., et al. Rapid-onset obesity with hypothalamic dysregulation,
400 hypoventilation, and autonomic dysregulation (ROHHAD syndrome): A case
401 report and literature review. *Neurologia.* 32,616-622 (2017).
- 402 4 Patwari, P.P. & Wolfe, L. Rapid-onset obesity with hypothalamic dysfunction,
403 hypoventilation, and autonomic dysregulation: review and update. *Curr Opin*
404 *Pediatr.* 26, 487-92 (2014).
- 405 5. Lee, J.M., et al. Rapid-Onset Obesity with Hypoventilation, Hypothalamic,
406 Autonomic Dysregulation, and Neuroendocrine Tumors (ROHHADNET)
407 Syndrome: A Systematic Review. *Biomed Res Int* 2018, 1-17 (2018).
- 408 6. Chew, H.B., Ngu, L.H., Keng, W.T. Rapid-onset obesity with hypothalamic
409 dysfunction, hypoventilation and autonomic dysregulation (ROHHAD): a case
410 with additional features and review of the literature. *BMJ Case Rep.* 2011 (2011).

- 411 7. Jacobson, L.A., et al. Improved Behavior and Neuropsychological Function in
412 Children With ROHHAD After High-Dose Cyclophosphamide. *Pediatrics* 138,
413 e20151080-e20151080 (2016).
- 414 8. Sethi, K., et al. ROHHADNET Syndrome Presenting as Major Behavioral
415 Changes in a 5-Year-Old Obese Girl. *Pediatrics* 134, e586-9 (2014).
- 416 9. Eldin, A.W.J., et al. Natural history of ROHHAD syndrome: development of
417 severe insulin resistance and fatty liver disease over time. *Clin. Diabetes*
418 *Endocrinol.* 5, 9 (2019).
- 419 10. Stowe, R.C. & Afolabi-Brown, O. Pulmonary hypertension and chronic
420 hypoventilation in ROHHAD syndrome treated with average-volume assured
421 pressure support. *Pediatr. Investig.* 3, 253-256 (2019).
- 422 11. Selvadurai, S., et al. Sleep-disordered breathing, respiratory patterns during
423 wakefulness and functional capacity in pediatric patients with rapid-onset obesity
424 with hypothalamic dysfunction, hypoventilation and autonomic dysregulation
425 syndrome. *Pediatr. Pulmonol.* 56, 479-485 (2021).
- 426 12. Kocaay P., Şıklar Z., Çamtosun E., Kendirli T., Berberoğlu, M. ROHHAD
427 Syndrome: Reasons for Diagnostic Difficulties in Obesity. *J Clin Res Pediatr*
428 *Endocrinol.* 6, 254-257 (2016).
- 429 13. Barclay, S.F., et al. ROHHAD and Prader-Willi syndrome (PWS): Clinical and
430 genetic comparison. *Orphanet J Rare Dis* 13, 1-9 (2018).
- 431 14. Barclay, S.F., et al. Absence of mutations in HCRT, HCRTR1 and HCRTR2 in
432 patients with ROHHAD. *Respir Physiol Neurobiol* 221, 59-63 (2016).

- 433 15 Cielo, C. and Marcus, C.L. Central Hypoventilation Syndromes. *Sleep Med Clin.*
434 9, 105-118 (2014).
- 435 16. Barclay, S.F., et al. Rapid-Onset Obesity with Hypothalamic Dysfunction,
436 Hypoventilation, and Autonomic Dysregulation (ROHHAD): exome sequencing of
437 trios, monozygotic twins and tumours. *Orphanet J Rare Dis* 10, 103 (2015).
- 438 17. Patwari, P.P., Rand, C.M., Berry-Kravis, E.M., Ize-Ludlow, D., Weese-Mayer,
439 D.E. Monozygotic twins discordant for ROHHAD phenotype. *Pediatrics* 128,
440 e711-5 (2011).
- 441 18. Rand, C., et al. Rapid-Onset Obesity With Hypothalamic Dysfunction,
442 Hypoventilation, and Autonomic Dysregulation: Analysis of Hypothalamic and
443 Autonomic Candidate Genes. *Pediatr Res* 70, 375-378 (2011).
- 444 19. Thaker, V.V., et al. Whole exome sequencing identifies RAI1 mutation in a
445 morbidly obese child diagnosed with ROHHAD syndrome. *J Clin Endocrinol* 100,
446 1723-30 (2005).
- 447 20. Harvengt, J., et al. ROHHAD(NET) Syndrome: Systematic Review of the Clinical
448 Timeline and Recommendations for Diagnosis and Prognosis. *J. Clin.*
449 *Endocrinol. Metab.* 105, 2119-2131 (2020).
- 450 21. Zaidi, S., Gandhi, J., Vatsia, S., Smith, N.L., Khan, S.A. Congenital central
451 hypoventilation syndrome: An overview of etiopathogenesis, associated
452 pathologies, clinical presentation, and management. *Auton Neurosci.* 210,1-9
453 (2018).

- 454 22. Meena, J.P., et. al. Neuroblastoma presenting as opsoclonus-myoclonus: A
455 series of six cases and review of literature. *J Pediatr Neurosci.* 11, 373-377
456 (2016).
- 457 23. Rudnick, E., et al. Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma:
458 Clinical outcome and antineuronal antibodies-a report from the children's cancer
459 group study. *Med Pediatr Oncol.* 36, 612-22 (2001).
- 460 24. Gharial, J. et al. Neuroimaging and Pathology Findings Associated With Rapid
461 Onset Obesity, Hypothalamic Dysfunction, Hypoventilation, and Autonomic
462 Dysregulation (ROHHAD) Syndrome. *J. Pediatr. Hematol. Oncol.* 43, e571-e576
463 (2020).
- 464 25. Nunn, K., Ouvrier, R., Sprague, T., Arbuckle, S., Docker, M. Idiopathic
465 Hypothalamic Dysfunction: A Paraneoplastic Syndrome? *Journal of Child*
466 *Neurology* 12, 276-281 (1997).
- 467 26. Cemeroglu, A.P., Eng, D.S., Most, L.A., Stalsonburg, C.M., Kleis, L. Rapid-onset
468 obesity with hypothalamic dysfunction, hypoventilation, and autonomic
469 dysregulation syndrome and celiac disease in a 13-year-old girl: Further
470 evidence for autoimmunity? *J Pediatr Endocrinol Metab* 29, 97-101 (2016).
- 471 27. Sirvent, N., et al. Hypothalamic dysfunction associated with neuroblastoma:
472 evidence for a new Paraneoplastic syndrome? *Med Pediatr Oncol* 40, 326-8
473 (2003).
- 474 28. Sartori, S., et al. Intrathecal synthesis of oligoclonal bands in rapid-onset obesity
475 with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation

- 476 syndrome: new evidence supporting immunological pathogenesis. *J Child Neurol*
477 29, 421-5 (2014).
- 478 29. Armangue, T., Petit-Pedrol, M., Dalmau J. Autoimmune encephalitis in children. *J*
479 *Child Neurol.* 27, 1460-9 (2012).
- 480 30. Paz-Prie, I. I., Cooke, D.W., Chen, A.R. Cyclophosphamide for rapid-onset
481 obesity, hypothalamic dysfunction, hypoventilation, and autonomic dysregulation
482 syndrome. *J Pediatr* 158, 337-9 (2011).
- 483 31. Huppke, P., Heise, A., Rostasy, K., Huppke, B., Gärtner, J. Immunoglobulin
484 therapy in idiopathic hypothalamic dysfunction. *Pediatr Neurol* 41, 232-4 (2009).
- 485 32. Voltz, R. Paraneoplastic neurological syndromes: an update on diagnosis,
486 pathogenesis, and therapy. *Lancet Neurol.* 1, 294-305 (2002).
- 487 33. Dalmau, J., and Graus, F. Antibody-Mediated Encephalitis. *New Engl J Med* 378,
488 840-851 (2018).
- 489 34. Giacomozzi, C., et al. Anti-Hypothalamus and Anti-Pituitary Auto-antibodies in
490 ROHHAD Syndrome: Additional Evidence Supporting an Autoimmune
491 Etiopathogenesis. *Horm.Res. Paediatr.* 92, 124-132 (2019).
- 492 35. Rathore, G.S., Thompson-Stone, R.I., Benson, L. Chapter 20: Rapid-Onset
493 Obesity with Hypothalamic Dysfunction, Hypoventilation, and Autonomic
494 Dysregulation (ROHHAD). In Waubant E, Lotze TE, eds: Pediatric Demyelinating
495 Diseases of the Central Nervous System and Their mimics: A Case-Based
496 Clinical Guide Edition 1. *Springer International Publishing* 159-16 (2017).

- 497 36. Dalmau, J. and Posner, J.B. Neurologic paraneoplastic antibodies (anti-Yo; anti-
498 Hu; anti-Ri). The case for a nomenclature based on antibody and antigen
499 specificity. *Neurology* 44, 2241 (1994).
- 500 37. Vanda A. Lennon. The case for a descriptive generic nomenclature
501 Clarification of immunostaining criteria for PCA-1, ANNA,-1, and ANNA-2
502 autoantibodies. *Neurology* 44, 2412 (1994).
- 503 38. Darnell, R.B. & Posner, J.B. Paraneoplastic Syndromes Involving the Nervous
504 System. *N Engl J Med.* 16; 349, 1543-1554 (2003).
- 505 39. Ances, B.M., et. al. Treatment-responsive limbic encephalitis identified by
506 neuropil antibodies: MRI and PET correlates. *Brain* 128, 1764-1777 (2005).
- 507 40. Lai, M., et. al. AMPA receptor antibodies in limbic encephalitis alter synaptic
508 receptor location. *Ann Neurol* 65, 424-434 (2009).
- 509 41. O'Donovan, B., et al. High-resolution epitope mapping of anti-Hu and anti-Yo
510 autoimmunity by programmable phage display, *Brain Communications*, 3;2,
511 fcaa059 (2020).
- 512 42. Mandel-Brehm, C., et al. Kelch-like Protein 11 Antibodies in Seminoma-
513 Associated Paraneoplastic Encephalitis. *N Engl J Med.* 4;381(1), 47-54 (2019).
- 514 43. Vazquez, S.E., et al. Identification of novel, clinically correlated autoantigens in
515 the monogenic autoimmune syndrome APS1 by proteome-wide PhIP-Seq. *Elife*
516 9, e55053 (2020).
- 517 44. Ruiz-García, R., Martínez-Hernández, E., Saiz, A., Dalmau, J., Graus, F. The
518 Diagnostic Value of Onconeural Antibodies Depends on How They Are Tested.
519 *Front Immunol.* 11, 1482. (2020).

- 520 45. Luchi. S. Three classes of C2H2 zinc finger proteins. *CMLS, Cell Mol. Life Sci.*
521 58, 625-635 (2001).
- 522 46. Dehal, P., et.al. Human chromosome 19 and related regions in mouse:
523 conservative and lineage-specific evolution. *Science* 293(5527):104-11. (2001)
- 524 47. Edelstein, L.C. & Collins, T. The SCAN domain family of zinc finger transcription
525 factors. *Gene* 10, 359:1-17 (2005).
- 526 48. Sander, T.L., et al. The SCAN domain defines a large family of zinc finger
527 transcription factors. *Gene* 310, 29-38 (2003).
- 528 49. Zhao, Y., et. al. RAPSearch2: a fast and memory-efficient protein similarity
529 search tool for next-generation sequencing data. *Bioinformatics*. 28,125-6
530 (2012).

531

532 **Acknowledgements**

533 This research was supported by ROHHAD Fight, Inc, the OMS Life Foundation, the
534 Repository Core for Neurological Disorders, Department of Neurology, Boston
535 Children's Hospital, and the IDDRRC (NIH P30HD018655) and NIH R01MH122471. We
536 would also like to acknowledge the New York Blood Center for contribution of healthy
537 control plasma. Instituto Carlos III (ISCIII, PI20/00197 [JD]), and "La Caixa" Foundation
538 (JD). CMA is supported by NIDDK (K23DK120899). Acknowledge the UCSF Nikon
539 Core Facility for microscope imaging equipment and guidance. JDL is funded by a grant
540 from Chan Zuckerberg Biohub. JDL, MRW, SJP and CMB are funded by the National
541 Institute of Mental Health (NIMH) of the NIH (award 1R01MH122471-01). SJP, BT are
542 also funded by the Brain Research Foundation (Scientific Innovations Award). CMB is

543 also funded by The Emiko Terasaki Foundation (Project 7027742 / Fund B73335) and
544 by the National Institute of Neurological Disorders and Stroke (NINDS) of the National
545 Institutes of Health (award 1K99NS117800-01). SEV is funded by the National Institute
546 of Diabetes and Digestive and Kidney Diseases of the NIH (award 1F30DK123915-01).

547

548 **Author contributions:**

549 CMB, LB and BT contributed equally to this work.

550

551

1 Main Figure and Tables

Patient No. and sex	Sample Type	ROHHAD Symptoms					Treatments#	Outcome
		Rapid-Onset Obesity?	Respiratory phenotype	Endocrinopathies†	Autonomic Dysfunction	Tumor Type and CSF Results		
1 (F)	CSF, Serum	Yes	CSA, 24 hour hypoventilation	Thirst dysregulation, AVP dysregulation (with DI and SIAD), hyperprolactinemia, HH, GHD, CH, CAI, obesity (Z=+2.5, peak +2.7), IR, T2D (metformin, insulin, GLP1RA)	Temperature and heart rate dysregulation, enuresis, duodenal pseudoobstruction	Ganglioneuroma; 1 white blood cell/m ³ , 8 red blood cells/m ³ , 0 OCBs	Tumor resection, trach/vent, IVIG, rituximab, MMF	Alive
2 (F) ³⁵	CSF, Serum	Yes	Night-time hypoventilation	Hyperprolactinemia, HH, GHD, obesity (Z=+2.4, peak +3.1), IR, prediabetes	Constipation, encopresis	Ganglioneuroma; 0 white blood cell/m ³ , 54 red blood cells/m ³ , matched CSF and serum OCBs	Tumor resection, CPAP, IVIG, Rituximab	Alive
3 (M)	CSF, Serum	Yes	CSA, 24 hour hypoventilation	Thirst dysregulation, AVP dysregulation (with DI and SIAD), prepubertal gonadotropins, GHD, CH, CAI (partial), obesity (Z=+2.6, peak +5.2)	Temperature instability, heart rate variability, severe constipation with rectal prolapse, episodic diaphoresis	Neuroblastoma; 5 white blood cell/m ³ , 525 red blood cells/m ³ , 13 OCBs at diagnosis	Tumor resection, trach/vent, IVIG, rituximab	Sudden death
4 (M)	CSF, Serum, Tumor	Yes	CSA, 24 hour hypoventilation	Hyperprolactinemia (resolved), obesity(Z=+3.1, peak +3.7)	Hypertension, severe paroxysmal sympathetic hyperactivity at times with flash pulmonary edema, (GI dysmotility	Ganglioneuroblastoma; 4 white blood cell/m ³ , 2 red blood cells/m ³ , 2 OCBs (normal), neopterin 20 (normal)	Tumor resection, trach/vent, methylprednisolone, IVIG, rituximab	Alive

					post arrest, improved)			
5 (M)	CSF, Serum, Tumor	Yes	CSA, 24 hour hypoventilation	SIAD, hyperprolactinemia, CH, obesity (Z=+4.7, peak 6.1)	Blood pressure, heart rate and temperature instability (severe hyperthermia up to 108F w/ brain injury), episodic diaphoresis	Ganglioneuroblastoma; 0 white blood cell/m3, 0 red blood cells/m3, 0 OCBs, neopterin 41 (normal) (repeat LP after 5.5 months similar now with matched CSF and serum OCBs)	Tumor resection, trach/vent, dexamethasone, IVIG, rituximab, high dose cyclophosphamide	Alive, severe debilitation and behavior problems
6 (M)**	CSF, Serum	Yes	24 hour hypoventilation	Thirst dysregulation, AVP dysregulation (with DI), hyperprolactinemia, CH, obesity (Z=+1.7, peak +3.9)	Transient temperature instability at diagnosis, episodic diaphoresis (all resolved with treatment)	Ganglioneuroblastoma, intermixed; 36 white blood cell/m3, 0 red blood cells/m3, 0 OCBs, neopterin 94 (elevated)	Tumor resection, BiPAP, dexamethasone, IVIG, rituximab	Alive
7 (F) ⁷	Serum	Yes	OSA	DI (partial)	None	Ganglioneuroblastoma	Rituximab, high dose cyclophosphamide	Alive
8 (F) ¹	CSF, Serum	Yes	24 hour hypoventilation	Mild hyperprolactinemia, Hypothyroidism, central precocious puberty, later amenorrhea, GHD, obesity (BMI 38.7 kg/m2 adulthood), recurrent hypoglycemia/hypokalemia in adulthood of unclear etiology	None diagnosed/evaluated in childhood	Ganglioneuroma; 2 white blood cell/m3, 60 red blood cells/m3, protein 141, 0 OCBs, neopterin 21 (normal)	Steroids, IVIG, rituximab, thymectomy	Alive

9 (M)	Serum	Yes	CSA, 24 hour hypoventilation	Hypodipsia, AVP dysregulation (with DI and hyponatremia), obesity (Z=+2.7, peak +4.7), IR, T2D (metformin, insulin)	Temperature instability, bradycardia, hypothermia, episodic diaphoresis	None (abdomen not imaged); 2 white blood cell/m3, 31 red blood cells/m3, 1 matched serum to CSF OCB, neopterin 76 (elevated)	IVIG	Sudden death
-------	-------	-----	------------------------------	---	---	--	------	--------------

2 **Table 1. Clinical profile of ROHHAD cohort.**

3 AVP = Arginine Vasopressin, BiPAP= Bilevel Positive Airway Pressure, BMI = Body Mass Index, CAI=central adrenal insufficiency,
4 CH=central hypothyroidism, CSF = Cerebrospinal Fluid, CPAP= Continuous Positive Airway Pressure, CSA= central sleep apnea,
5 DI= diabetes insipidus, GHD=growth hormone deficiency, GLP1RA = Glucagon-like peptide-1 receptor antagonists, LP= Lumbar
6 Puncture, HH=hypogonadotropic hypogonadism, IR=insulin resistance, IVIG = Intravenous Immunoglobulin, OCB = Oligoclonal
7 Band, MMF = Mycophenolate Mofetil, OSA = Obstructive Sleep Apnea, SIAD=syndrome of inappropriate antidiuresis, T2D=type 2
8 diabetes mellitus, trach=tracheostomy, vent = ventilator

9 * All tested CSF had normal protein, glucose and IgG index values except where noted

10 **See Supplemental Figure 1

11 #Endocrine and other symptomatic treatment not recorded.

12 †Body mass index (BMI) z-scores (number of standard deviations from average) based on the 2000 Centers for Disease Control
13 Growth Charts (https://www.cdc.gov/growthcharts/cdc_charts.htm) were abstracted by patient chart review.

14 ^{1,7,35} denote references for patients published previously.




Figure 1: PhIP-Seq screen implicates ZSCAN1 as a candidate autoantigen in ROHHAD. CSF from 3 ROHHAD patients (ROHHAD-1 to 3) and plasma from a large set of “healthy controls” (n = 100) were tested by PhIP-Seq. Individual data was averaged according to cohort. All proteins with a ROHHAD mean RP100K >0 are plotted against ROHHAD Z-score enrichments compared to healthy. Non-ZSCAN1 proteins are denoted with blue dots, ZSCAN1 is denoted with a red dot.




Figure 2. Validation of autoantibodies to ZSCAN1 in ROHHAD patients. In panel a and b, enrichment of ZSCAN1 by PhIP-Seq and Radio Ligand Binding Assay (RLBA)

was compared between ROHHAD patients (n=9), non-inflammatory healthy controls (n=24) and pediatric controls including children with OMS with and without NT (n=25) and an obesity patient with NT (n=1). Data represents the average of two independent technical replicates. **a**, PhIP-Seq analysis. Each column represents an individual sample. A heatmap of total ZSCAN1 RP100K is shown in the top row. To enable comparisons between the majority of samples with lower signal we added a ceiling value of 1000 RP100K. Z-score enrichments based on our 100 human donor dataset are plotted below, with samples that have Z-score enrichments > 3 colored with blue squares. Grey squares indicate Z-score < 3. **b**, RLBA testing immunoprecipitation of recombinant ZSCAN1 by ROHHAD patients and controls. For all samples, fold change was calculated by dividing by the mean value from control sera (n=17, mean = 20.83). **c**, Representative image showing immunostaining of 293T cells expressing full-length ZSCAN1 with human CSF and commercial antibody to ZSCAN1 (Rabbit). Top row shows immunostaining with control CSF. Bottom row shows staining with ROHHAD-3 CSF. Colocalization is indicated by yellow in the merge images (far right both rows).




Figure 3. Immunohistochemical detection of ZSCAN1 in NT associated with ROHHAD patient-3. Fixed NT tissue was immunostained with either (top) Anti-Rabbit-488 secondary alone or (bottom) primary antibody to ZSCAN1 (Rabbit) and Anti-Rabbit-488 Secondary. Green: Anti-Rabbit-488 secondary, Blue: DAPI to identify nuclei.